Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.
Cabozantinib is an oral multikinase inhibitor whose targets include vascular endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, based...
| Publicado en: | Targeted Oncology Vol. 15; no. 4; pp. 549 - 566 |
|---|---|
| Autores principales: | , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Aug2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145258646&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 145258646 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: Aug2020 vid: 15 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 145258646 145019978 145258646 NLM32770441 145258646 10.1007/s11523-020-00736-8 NLM32770441 145258646 ppf: 549 ppct: 17 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. aug: au: Schwartz, Gabriel Darling, Julianne O. Mindo, Malori Damicis, Lucia affil: Gastrointestinal Medical Oncology Clinic, University of California San Francisco, 1825 Fourth St, Fourth Floor, 94158, San Francisco, CA, USA sug: subj: Transferases Adverse Effects Carcinoma, Hepatocellular Complications Liver Neoplasms Drug Therapy Amides Adverse Effects Liver Neoplasms Complications Pyridines Adverse Effects Carcinoma, Hepatocellular Drug Therapy Male Transferases Pharmacodynamics Amides Pharmacodynamics Human Female Pyridines Pharmacodynamics Quality of Life Comparative Studies Multicenter Studies Evaluation Research Validation Studies Impact of Events Scale Scales Ferrans and Powers Quality of Life Index Male Female ab: Cabozantinib is an oral multikinase inhibitor whose targets include vascular endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, based on improved overall survival and progression-free survival relative to placebo in the phase III CELESTIAL study. During CELESTIAL, the most common adverse events (AEs) experienced by patients receiving cabozantinib included palmar-plantar erythrodysesthesia, fatigue, gastrointestinal-related events, and hypertension. These AEs can significantly impact treatment tolerability and patient quality of life. However, AEs can be effectively managed with supportive care and dose modifications. During CELESTIAL, more than half of the patients receiving cabozantinib required a dose reduction, while the rate of treatment discontinuation due to AEs was low. Here, we review the safety profile of cabozantinib and provide guidance on the prevention and management of the more common AEs, based on current evidence from the literature as well as our clinical experience. We consider the specific challenges faced by clinicians in treating this patient population and discuss factors that may affect exposure and tolerability to cabozantinib. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|